Jarkko Huuskonen

Lake N. Paul, PhD. is in San Diego at the Biotechnology Innovation Organization #BIO2024 conference meeting with colleagues & future clients. Connect with him in person to learn about how, as a Collaborative Research Organization, we are best positioned to support your analytical program. #aav #genetherapy #rarediseases #biophysics #STEM #STEMPhilly #biochemistry #celltherapy #bioanalysisllc #PhillyBusiness #phillyscience

9

We are thrilled to share the presentation of Stephanie Chrysanthou, PhD, our R&D Manager at Integrated Genomics Operation Memorial Sloan Kettering Cancer Center, on detection of germline alterations in solid #cancer patient samples by adaptive sampling 🙌 presented at the Nanopore Community Meeting conference in Boston! Our core has closely partnered with the Molecular Pathology & Diagnostics lab to benchmark Adaptive Sampling long read #sequencing for detecting germline #mutations against prior MSK-IMPACT profiles generated by hybridization capture short-read sequencing. Adaptive Sampling is a promising approach due to reduced technical complexity and TAT, there is no need for sample batching and it facilitates the resolution of large complex structural #variants. Due to the live #basecalling capacity of the #nanopore technology, the sequencing can be stopped if a fragment does not match the uploaded target .bed file, thus enriching on-target fragment #sequencing. Briefly, our on-instrument data workflow includes: 1) filtering of the raw .pod5 files based on the on-target decision, 2) SUP basecalling, 3) GRCh38 alignment, 4) SNV/SV calling using #EPI2ME and #SEVERUS pipelines.  On a routine basis, this workflow, from #hmwDNA extraction to data analysis, takes 3.5 days. Feel free to watch the full presentation here 👇 (it's free to register and you'll get access to all ONT conference presentations!) Oxford Nanopore Technologies https://lnkd.in/ezE_vsYT

49

2 Comments

Event Recap: 6th Annual Cell Therapy Analytical Development Summit  What an incredible gathering at the Cell Therapy Analytical Development Summit! We were honored to have LumaCyte's President and CBO, Renee A. Hart, join industry leaders Ramon Mendoza, Alexandre Ambrogelly, and Stephan O. Krause, PhD, for the Industry Leaders’ Fireside Chat. Their discussion on "Pioneering Analytical Frontiers to Overcome the Complexities of Cell Therapy Products" offered invaluable insights from some of the foremost analytical minds in the field.   We were also thrilled to see Colin Hebert, LumaCyte’s Senior Vice President of Scientific & Business Operations, present at the summit. His session on "Quantitative Cell Characterization Using Laser Force Cytology™ (LFC): Predictive Insights into CAR T Donor Variability" was standing room only and showcased the transformative potential of LFC as a quantitative label-free precision PAT. Colin's insights on the correlation of CAR T potency with donor cellular starting material and T-cell activation road mapping illustrated the powerful impact predictive analytics can bring to advanced therapy manufacturing.    Additionally, Laura Pierce from NIST gave a fantastic talk on the importance of precise cell viable state analytics highlighting some work that she and her team have been doing at NIST with Laser Force Cytology.    Thank you to everyone who attended and contributed to the success of this event. Stay tuned for more exciting updates and advancements from LumaCyte!   #CellTherapy #AnalyticalDevelopment #LumaCyte #Innovation #Healthcare #SummitRecap

26

3 Comments

Cell's fifth focus issue celebrating the journal's 50th anniversary expands upon its first anniversary focus issue on cell biology by directing our focus toward the future of the field. “Cell biology is so entwined with the origin of Cell and is growing in such exciting directions that we couldn’t stop with one 50th anniversary focus on the area,” says the Cell editorial team. “There are too many questions to ask.” This issue showcases areas where cell biology is forging ahead, including fresh looks at mitochondria and the concept of cell state alongside ideas about how to train the next generation of researchers. Learn about the people, technologies, and research driving the field of cell biology into the future. Explore the issue: https://lnkd.in/gtZU2iw9 #50YearsofCell

50

On January 8, 2025, Avidity Biosciences, Inc. announced its progress and planning for a transformational year in 2025. #DuchenneNews Major anticipated milestones include executing on three potentially registrational programs, filing a Biologics License Application for delpacibart zotadirsen (del-zota) for people living with Duchenne mutations amenable to exon 44 skipping (DMD44), preparing for multiple product launches in DMD44, myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD) and building a global, fully integrated company to support a growing AOC pipeline in neuromuscular diseases and precision cardiology. Full press release: https://bit.ly/40hG1RF

5

Tune in to our webinar, "Advancing Precision Oncology: Radionuclide Conjugate & Antibody Conjugate Development Strategies," where our A-Team of experts will dive into topics such as regulatory and submissions optimization, Project Optimus implications, clinical pharmacology considerations, and more. Allucent experts Alex MacDonald, PhD (VP, Model-Informed Drug Development), Sugato De, MS (VP, Regulatory Strategy, Head of MedTech), Angela Brady, MHL (Sr. VP, Global Head of Project Leadership and Client Relations), and Brian Barnett, MD (Executive Medical Director) will discuss the current landscape of antibody-drug conjugates and radionuclide conjugates (Learn more: https://lnkd.in/gsCiscDZ). #Allucent #BringNewTherapiesToLight #CRO #RegulatoryAffairs #AntibodyDrugConjugates #RadionuclideConjugates

63

1 Comment

FDA approved 13 antibody-drug conjugates (ADCs) for clinical use. Look past the horizon at programs currently underway in this fast-growing space. https://hubs.ly/Q02_nL2p0

30

1 Comment

Last week, our President and Chief Science Officer – Bikash Chatterjee served as chair for a presentation on “Barriers and Opportunities for Using Prior Knowledge to Expedite Drug Development and Approval” at the 2024 #NIPTE conference in Washington, DC. The FDA is shifting gears with their new #PlatformDesignation and #AdvancedManufacturing guidance. 💡 Here’s what matters most: ✅ Use Your Knowledge: Clearly define where your team uses prior vs. platform knowledge in your regulatory strategy. ✅ Talk to the FDA: Don’t wait! Connect early and often to simplify your path and avoid extra development steps. ✅ Modeling is the Future: FDA and industry agree—modeling drives efficiency in drug development and manufacturing. ✅ Invest in Data: Build systems to manage the data and models behind your innovation. #FDAUpdates #DrugDevelopment #InnovationInMedicine

28

Our VP of Biochemistry & Chemical Biology Jacob Stuckey, PhD is presenting at American Association for Cancer Research’s Conference on Optimizing Therapeutic Efficacy & Tolerability through Cancer Chemistry today, 12/10 from 2 - 4 pm EST at Plenary Session 4: Drug Design and Optimization - New and emerging targets! Come learn more about our PPARg covalent inverse agonist, FX-909, #FlareTx’s lead candidate for the treatment of bladder cancer. Read more about our science & approach: https://lnkd.in/gRHddDE #biotech #oncology #drugdiscovery

55

1 Comment

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

Dive into the future of biomedical research with an informative webinar on the Human Pangenome Reference Consortium (HPRC)! Discover how to: ✅Access HPRC data ✅Perform variant analyses ✅Map functional genomics data to the pangenome. Register now: https://lnkd.in/eeXp2gKu #ASHG #HumanGenetics

18

Discover Silo's research in development through collaboration with the University of Maryland. SPU-16 targets #multiplesclerosis, the most common neurological disorder among young adults. Learn more about our drug here: https://bit.ly/40vPhAN #Science #Biotech #Biotechnology #Biopharma #MultipleSclerosis

3

At SRI Biosciences, we develop transformative approaches and platforms for challenging therapeutic problems. Conducting basic and translational research, our projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies. Learn more from division president, Kathlynn Brown, about who we are and what we do: https://lnkd.in/e-EKhg9D Attending BIO @ JPM this week and want to connect with us? Reach out in the partnering portal: https://bpjw.bio.org/ #JPM2025 #precisionmedicine #therapeutics Biotechnology Innovation Organization

14

From MBoC Baseline Unfolded Protein Response Signaling Adjusts the Timing How is ER integrity maintained during cell division? Zappa et al. latest study reveals how Unfolded Protein Response baseline signaling influences cell division dynamics. Dive into organelle inheritance and cellular signaling intersection with their new findings. #UPR #ISR #PERK #CellCycle https://lnkd.in/e8uxHmW7

1

🎯 Start Your Day at the Antibody Therapeutics Xchange with Rachel Fong! 🎯 We're excited to kick off the Antibody Therapeutics Xchange - Maryland 2024 with an insightful Opening Address & Keynote Presentation by Rachel Fong, Director of Strategic Partnerships at Integral Molecular. 🌟 ✨ REGISTER NOW and get your Complimentary Pass! https://lnkd.in/eqvCJ5MG 📅 Date: Monday, 28 October 2024 ⏰ Time: 08:30 AM - 09:00 AM 📍 Location: Marriott College Park, Maryland 💡 What to Expect: 🔬 Learn how cell-based protein arrays like the Membrane Proteome Array (MPA) are transforming antibody specificity testing. ⚙️ Understand the impact of off-target binding and how it contributes to drug attrition and patient risks. 🧪 Rachel Fong with over 10 years at Integral Molecular, has been a key player in launching the MPA platform and managing high-impact collaborations. As a co-author of over a dozen publications, she brings an expert perspective on guiding projects from concept to success. Don't miss this chance to dive deep into cutting-edge solutions that are shaping the future of antibody-based therapies! 🌍🔗 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #AntibodyTherapeutics #Biotech #Pharma #DrugDevelopment #AntibodyEngineering #Polyspecificity #IntegralMolecular #MembraneProteomeArray #AntibodySpecificity #TherapeuticInnovation #PharmaceuticalResearch #Biopharma #AntibodyDiscovery #MPATechnology #BiotechnologyEvent #TherapeuticDevelopment #ClinicalResearch #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

8

Before we pull out the champagne to ring in the new year, we're celebrating 2024 on the Translating Proteomics podcast by highlighting 3 our favorite proteomics publications from the year! In this episode, hosts Parag Mallick and Andreas Huhmer discuss 3 great publications covering pre-clinical work using proteomics, basic research using proteomics, and technology development in proteomics: https://lnkd.in/g-cxtQDK Congrats to all the authors behind this fantastic research including Bernhard Kuster, Stephan Eckert, Nicola Berner, Julia Muenzner, Pauline Trébulle, Markus Ralser, Judith Berman, Keisuke Motone, Daphne K., Jeff Nivala, and many more! And if your favorite publication wasn't featured, be sure to share it with us in the replies or by emailing it to translatingproteomics@nautilus.bio. We may feature it in a future episode. #Proteomics #NewYear #Science #Research #Proteome #Biology #TranslatingProteomics #UnleashTheProteome

8

Personalis, Inc. and Myriad Genetics have announced a cross-licensing agreement to enhance their operations and elevate MRD cancer testing results. For more details on this partnership and their previous collaborations, check out Precision Medicine Online's story! #MRD #Partnership #Oncology #MRDTest #CancerTest #PrecisionOncology

1